Comparision of Perioperative Fluoropyrimidine, Docetaxel And Oxaliplatin Regimen with Adjuvant Fluoropyrimidine and Oxaliplatine Regimen In Operable Gastric Cancer Patients

Authors : Aslı Yıldırım, Zeynep Ergenç, Nihal Bozdağ Kaplan, Hasan Ergenç

Pages : 248-256

Doi:10.34084/bshr.1591847

View : 28 | Download : 62

Publication Date : 2024-12-31

Article Type : Research Paper

Abstract :Aim: As no study has compared perioperative 5-Fluorouracil (5-FU), oxaliplatin, and docetaxel (FLOT) chemotherapy regimens with postoperative adjuvant oral capecitabine and oxaliplatin/5-FU and oxaliplatin (CAPEOX/FOLFOX) chemotherapy regimens, the goal of this study was to compare them in terms of median and overall survival of operable gastric cancers. Methods: This single-center, retrospective study recruited 59 subjects (17 females and 42 males) with at least T2 or more invasive gastric cancers with or without positive lymph node(s). All the patients underwent total or subtotal ((sub) total) gastric resection with D2 lymph node dissection. The Statistical Package for the Social Sciences (IBM SPSS) 26.0 program was used to statistically analyze the research findings. Results: The peri-operative FLOT treatment group with 30 patients displayed significantly more advanced clinical nodal (cN) stage (p<0.005), more comorbidities (p=0.025), and worse Eastern Cooperative Oncology Group (ECOG) performance (p=0.007) during diagnosis than the adjuvant CAPEOX/FOLFOX treatment group (29 patients). The median overall survival (mOS) and median progression free survival (mPFS) were found to be statistically significant (21 vs. 14 months, p=0.018 and 17 versus 8.5 months p=0.009, respectively) higher in favor of the adjuvant treatment group. Conclusion: According to real-life data, younger and earlier stage patients who chose surgery as the first treatment option to eliminate cancer as soon as possible had longer mOS and mPFS.
Keywords : Gastrik, kanser, neoadjuvan, adjuvan, tedavi.